{"success":true,"data":{"pressRelease":{"id":"160962","rtpr_id":"nPn1XZSs8a-20261005","ticker":"GRAL","exchange":"NASDAQ","all_tickers":["GRAL"],"title":"GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at EDCC and ESMO Congress 2026","author":"PR Newswire","published_at":"2026-10-05T20:01:00.051Z","article_body":"GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at EDCC and ESMO Congress 2026\nPR Newswire\n\nSUNNYVALE, Calif., Oct. 5, 2026\n\nGRAIL to Present Six Abstracts at the Early Detection of Cancer Conference\n(EDCC) Spanning Clinical Performance, Health Equity, and Real-World\nImplementation of Multi-Cancer Early Detection\n\nGRAIL to Present Two Abstracts at the European Society for Medical Oncology\n(ESMO) Congress, Across the Cancer Diagnostic Journey and Real-World Evidence\n\nSUNNYVALE, Calif., Oct. 5, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a\nhealthcare company whose mission is to detect cancer early when it can be\ncured, will present additional data from both the NHS-Galleri trial and the\nPATHFINDER 2 study further evaluating the Galleri(®) multi-cancer early\ndetection (MCED) test at the Early Detection of Cancer Conference (EDCC) in\nEdinburgh, the United Kingdom, taking place Oct. 6-8, 2026, and at the\nEuropean Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain\ntaking place Oct. 23-27, 2026.\n\nData across both meetings will include:\n\n * A rapid oral presentation highlighting the efficiency and safety of Cancer\nSignal Origin (CSO) guided diagnostic workups.\n * A poster showing Galleri cancer detection of more than 200 cancers across\nhistologically distinct cancer types, including rare cancers.\n * A poster showing Galleri cancer detection performance and accuracy across\nself-reported racial and ethnic groups.\n * A poster presenting new NHS-Galleri data on the preclinical window for cancer\ndetection with findings compatible with annual MCED screening.\n * A poster showing a reduction of cancer diagnoses in emergency presentations\nassociated with annual Galleri screenings.\n\"Ongoing analyses of PATHFINDER 2 and NHS-Galleri trial data continue to\nstrengthen the evidence for integrating multi-cancer early detection into\nroutine care,\" said Josh Ofman, MD, MSHS, CEO at GRAIL. \"Across large, diverse\npopulations, these data continue to demonstrate Galleri's strong performance\nand favorable safety profile, and reinforce its potential to fundamentally\nimprove how we screen for cancer by finding more cancers, before symptoms are\npresent, in early stages, when there is the greatest opportunity for curative\nintent treatment.\"\n\nEDCC Data Presentations\n\nTitle: Estimating Preclinical Detection Window, Multi-Cancer Early Detection\n(MCED) Test Sensitivity, and Episode Sensitivity in the NHS-Galleri Trial\nUsing the Incidence Method\nPresentation Type: Poster\nDate: Oct. 6\n\nTitle: Spectrum of Histologically Distinct Cancer Types Detected by a\nMethylation-Based Multi-Cancer Early Detection (MCED) Test\nPresentation Type: Poster\nDate: Oct. 7\n\nTitle: Performance of a multi-cancer early detection (MCED) test across racial\nand ethnic groups: Descriptive report from PATHFINDER 2\nPresentation Type: Poster\nDate: Oct. 7\n\nTitle: Loss of Life Expectancy by Stage at Diagnosis and Cancer Type in\nEngland: Illustrating the Burden of Premature Mortality From Late-Stage Cancer\nPresentation Type: Poster\nDate: Oct. 6\n\nTitle: High adherence to mammography screening before and after MCED testing\nPresentation Type: Poster\nDate: Oct. 7\n\nTitle: Population Impact of MCED Screening by Reducing the Diagnosis of Cancer\nin Emergency Settings in England\nPresentation Type: Poster\nDate: Oct. 7\n\nMore information about timing of the EDCC presentations can be found here\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4789959-1&h=3636076942&u=https%3A%2F%2Fwww.earlydetectionresearch.com%2F&a=here)\n.\n\nESMO Data Presentations\n\nTitle: Efficiency and Safety of Cancer Signal Origin (CSO)-Guided Diagnostic\nWorkups Following Multi-Cancer Early Detection (MCED) Testing: Results from\nPATHFINDER 2 (PF2)\nAbstract Number: 1151\nPresentation Type: Rapid Oral\nDate/Time: Oct. 26, 2:45 p.m.-4:15 p.m.\nLocation: Salamanca Auditorium, Hall 10\n\nTitle: Diagnostic Workups Following a Positive Multi-Cancer Early Detection\n(MCED) Blood Test in Clinical Practice\nPresentation Number: 1164P\nPresentation Type: Poster\nDate/Time: Oct. 25, 12 p.m.-12:45 p.m.\n\nMore information about timing of the ESMO presentations can be found here\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4789959-1&h=1993774795&u=https%3A%2F%2Fcslide.ctimeetingtech.com%2Fesmo2026%2Fattendee%2Fconfcal%2Fsession%2Flist&a=here)\n.\n\nAbout GRAIL\nGRAIL is a healthcare company whose mission is to detect cancer early, when it\ncan be cured. GRAIL is focused on alleviating the global burden of cancer by\nusing the power of next-generation sequencing, population-scale clinical\nstudies, and state-of-the-art machine learning, software, and automation to\ndetect and identify multiple deadly cancer types in earlier stages. GRAIL's\ntargeted methylation-based platform can support the continuum of care for\nscreening and precision oncology, including multi-cancer early detection in\nsymptomatic patients, risk stratification, minimal residual disease detection,\nbiomarker subtyping, treatment and recurrence monitoring. GRAIL is\nheadquartered in Sunnyvale, Calif. with locations in Washington, D.C., North\nCarolina, and the United Kingdom.\n\nFor more information, visit grail.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4789959-1&h=1713412373&u=http%3A%2F%2Fwww.grail.com%2F&a=grail.com)\n.\n\nAbout Galleri(®)\nThe Galleri(®) multi-cancer early detection (MCED) test screens for more\nthan 50 cancer types, including many deadly cancers that currently lack\nscreening options, such as pancreatic, ovarian, and liver/bile duct\ncancers(1). The Galleri test is the only MCED test clinically proven through a\nrandomized controlled trial to increase earlier cancer detection (Stage I-III)\nand reduce Stage IV diagnoses - enabling more patients to have access to\npotentially curative treatment options(2). When added to standard-of-care\nscreening, the Galleri test reduced Stage IV diagnosis by more than 20% after\nthe first year of screening across all stageable cancers(2,)*. The Galleri\ntest increased cancer detection by screening four times versus standard of\ncare screening alone(2). The Galleri test has the lowest false positive rate\namong MCED tests** and the ability to predict the Cancer Signal Origin with\ngreater than 90% accuracy, helping guide efficient diagnostic\nevaluation(1-)(3). The Galleri test is backed by a robust clinical evidence\nprogram, with more than 380,000 participants across multiple studies,\nincluding the NHS-Galleri trial, the first and only randomized controlled\ntrial for an MCED test. The Galleri test has delivered consistent performance\nacross these studies. The Galleri test requires a prescription from a licensed\nhealthcare provider and should be used in addition to recommended cancer\nscreenings, such as mammography, colonoscopy, prostate-specific antigen (PSA)\ntest, cervical or lung cancer screening. The Galleri test is recommended for\nadults with an elevated risk for cancer, such as those aged 50 years or older.\n\nFor more information, visit galleri.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4789959-1&h=2832277109&u=http%3A%2F%2Fgalleri.com%2F&a=galleri.com)\n.\n\n*A statistically significant reduction was not observed in combined stage\nIII–IV diagnoses across three screening rounds for 12 cancer types\nresponsible for around two-thirds of cancer mortality in the US and UK.\n\n**Test performance metrics do not represent results of a head-to-head\ncomparative study. Separate studies have different designs, objectives, and\nparticipant populations, which limits the ability to draw conclusions about\ncomparative performance.\n\nImportant Galleri Safety Information\nThe Galleri test is recommended for use in adults with an elevated risk for\ncancer, such as those age 50 years or older. The test does not detect all\ncancers and should be used in addition to routine cancer screening tests\nrecommended by a healthcare provider. The Galleri test is intended to detect\ncancer signals and predict where in the body the cancer signal is located. Use\nof the test is not recommended in individuals who are pregnant, 21 years old\nor younger, or undergoing active cancer treatment. Results should be\ninterpreted by a healthcare provider in the context of medical history,\nclinical signs, and symptoms. A test result of No Cancer Signal Detected does\nnot rule out cancer. A test result of Cancer Signal Detected requires\nconfirmatory diagnostic evaluation by medically established procedures (e.g.,\nimaging) to confirm cancer. If cancer is not confirmed with further testing,\nit could mean that cancer is not present or testing was insufficient to detect\ncancer, including due to the cancer being located in a different part of the\nbody. False positive (a cancer signal detected when cancer is not present) and\nfalse negative (a cancer signal not detected when cancer is present) test\nresults do occur. Rx only.\n\nLaboratory/Test Information\nThe GRAIL clinical laboratory is certified under the Clinical Laboratory\nImprovement Amendments of 1988 (CLIA) and accredited by the College of\nAmerican Pathologists. The Galleri test was developed — and its performance\ncharacteristics were determined — by GRAIL. The Galleri test has not been\ncleared or approved by the Food and Drug Administration. The GRAIL clinical\nlaboratory is regulated under CLIA to perform high-complexity testing. The\nGalleri test is intended for clinical purposes.\n\nGRAIL Forward Looking Statements\nThis press release contains forward-looking statements. In some cases, you can\nidentify these statements by forward-looking words such as \"aim,\"\n\"anticipate,\" \"believe,\" \"continue,\" \"could,\" \"estimate,\" \"expect,\" \"intend,\"\n\"may,\" \"might,\" \"plan,\" \"potential,\" \"predict,\" \"should,\" \"would,\" or \"will,\"\nthe negative of these terms, and other comparable terminology. These\nforward-looking statements, which are subject to risks, uncertainties, and\nassumptions about us, may include statements related to the potential\nbenefits, uses and impacts of the Galleri test, comparability of clinical\nstudy results to a real world setting, benefits of population screening with\nexisting or future versions of Galleri, the substance, format and scope of the\nclinical data to be presented at the EDCC and ESMO Congress, and the\nevidentiary effect and clinical implications of additional clinical data and\nanalyses on the potential benefits, uses and impacts of the Galleri test,\namong others.\n\nThese statements are only predictions based on our current expectations and\nprojections about future events and trends. There are important factors that\ncould cause our actual results, level of activity, performance, or\nachievements to differ materially and adversely from those expressed or\nimplied by the forward-looking statements, including those factors and\nnumerous associated risks discussed under the sections entitled \"Risk Factors\"\nin our Annual Report on Form 10-K for the period ended December 31, 2025 and\nour subsequent Quarterly Reports on Form 10-Q. Moreover, we operate in a\ndynamic and rapidly changing environment. New risks emerge from time to time.\nIt is not possible for our management to predict all risks, nor can we assess\nthe impact of all factors on our business or the extent to which any factor,\nor combination of factors, may cause actual results, level of activity,\nperformance, or achievements to differ materially and adversely from those\ncontained in any forward-looking statements we may make.\n\nForward-looking statements relate to the future and, accordingly, are subject\nto inherent uncertainties, risks, and changes in circumstances that are\ndifficult to predict and many of which are outside of our control. Although we\nbelieve the expectations and projections expressed or implied by the\nforward-looking statements are reasonable, we cannot guarantee future results,\nlevel of activity, performance, or achievements. Our actual results, financial\ncondition and success in our business strategies and operations may differ\nmaterially from those indicated in the forward-looking statements. Except to\nthe extent required by law, we undertake no obligation to update any of these\nforward-looking statements after the date of this press release to conform our\nprior statements to actual results or revised expectations or to reflect new\ninformation or the occurrence of unanticipated events.\n\n(1) Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted\nmethylation-based multi-cancer early detection test using an independent\nvalidation set. Ann Oncol. 2021 Sep;32(9):1167-77. doi:\n10.1016/j.annonc.2021.05.806\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4789959-1&h=3964125602&u=https%3A%2F%2Fwww.annalsofoncology.org%2Farticle%2FS0923-7534(21)02046-9%2Ffulltext&a=10.1016%2Fj.annonc.2021.05.806)\n\n(2) Swanton C. NHS-Galleri: Primary Results From a Randomised Controlled\nTrial to Assess the Clinical Utility of a Multi-Cancer Early Detection (MCED)\nTest in Population Screening [presentation]. American Society of Clinical\nOncology (ASCO) Annual Meeting; 2026 May 29-June 2.\n\n(3) GRAIL, Inc. False positive rate. [Data on file: GR-2025-0256]\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/grail-to-present-new-data-from-nhs-galleri-and-pathfinder-2-at-edcc-and-esmo-congress-2026-302898855.html\n(https://www.prnewswire.com/news-releases/grail-to-present-new-data-from-nhs-galleri-and-pathfinder-2-at-edcc-and-esmo-congress-2026-302898855.html)\n\nSOURCE GRAIL, Inc.\n\n\n\nCorporate Communications, Kristen Ziese or Trish Rowland, pr@grail.com or Investor Relations, Alex Dobbin or Alexis Tosti, ir@grail.com\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1579281/Grail-Logo.jpg?id=OA2988272\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn1XZSs8a-20261005","title":"GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at EDCC and ESMO Congress 2026","author":"PR Newswire","ticker":"GRAL","created":"2026-10-05T20:01:00.051Z","tickers":["GRAL"],"exchange":"NASDAQ","article_body":"GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at EDCC and ESMO Congress 2026\nPR Newswire\n\nSUNNYVALE, Calif., Oct. 5, 2026\n\nGRAIL to Present Six Abstracts at the Early Detection of Cancer Conference\n(EDCC) Spanning Clinical Performance, Health Equity, and Real-World\nImplementation of Multi-Cancer Early Detection\n\nGRAIL to Present Two Abstracts at the European Society for Medical Oncology\n(ESMO) Congress, Across the Cancer Diagnostic Journey and Real-World Evidence\n\nSUNNYVALE, Calif., Oct. 5, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a\nhealthcare company whose mission is to detect cancer early when it can be\ncured, will present additional data from both the NHS-Galleri trial and the\nPATHFINDER 2 study further evaluating the Galleri(®) multi-cancer early\ndetection (MCED) test at the Early Detection of Cancer Conference (EDCC) in\nEdinburgh, the United Kingdom, taking place Oct. 6-8, 2026, and at the\nEuropean Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain\ntaking place Oct. 23-27, 2026.\n\nData across both meetings will include:\n\n * A rapid oral presentation highlighting the efficiency and safety of Cancer\nSignal Origin (CSO) guided diagnostic workups.\n * A poster showing Galleri cancer detection of more than 200 cancers across\nhistologically distinct cancer types, including rare cancers.\n * A poster showing Galleri cancer detection performance and accuracy across\nself-reported racial and ethnic groups.\n * A poster presenting new NHS-Galleri data on the preclinical window for cancer\ndetection with findings compatible with annual MCED screening.\n * A poster showing a reduction of cancer diagnoses in emergency presentations\nassociated with annual Galleri screenings.\n\"Ongoing analyses of PATHFINDER 2 and NHS-Galleri trial data continue to\nstrengthen the evidence for integrating multi-cancer early detection into\nroutine care,\" said Josh Ofman, MD, MSHS, CEO at GRAIL. \"Across large, diverse\npopulations, these data continue to demonstrate Galleri's strong performance\nand favorable safety profile, and reinforce its potential to fundamentally\nimprove how we screen for cancer by finding more cancers, before symptoms are\npresent, in early stages, when there is the greatest opportunity for curative\nintent treatment.\"\n\nEDCC Data Presentations\n\nTitle: Estimating Preclinical Detection Window, Multi-Cancer Early Detection\n(MCED) Test Sensitivity, and Episode Sensitivity in the NHS-Galleri Trial\nUsing the Incidence Method\nPresentation Type: Poster\nDate: Oct. 6\n\nTitle: Spectrum of Histologically Distinct Cancer Types Detected by a\nMethylation-Based Multi-Cancer Early Detection (MCED) Test\nPresentation Type: Poster\nDate: Oct. 7\n\nTitle: Performance of a multi-cancer early detection (MCED) test across racial\nand ethnic groups: Descriptive report from PATHFINDER 2\nPresentation Type: Poster\nDate: Oct. 7\n\nTitle: Loss of Life Expectancy by Stage at Diagnosis and Cancer Type in\nEngland: Illustrating the Burden of Premature Mortality From Late-Stage Cancer\nPresentation Type: Poster\nDate: Oct. 6\n\nTitle: High adherence to mammography screening before and after MCED testing\nPresentation Type: Poster\nDate: Oct. 7\n\nTitle: Population Impact of MCED Screening by Reducing the Diagnosis of Cancer\nin Emergency Settings in England\nPresentation Type: Poster\nDate: Oct. 7\n\nMore information about timing of the EDCC presentations can be found here\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4789959-1&h=3636076942&u=https%3A%2F%2Fwww.earlydetectionresearch.com%2F&a=here)\n.\n\nESMO Data Presentations\n\nTitle: Efficiency and Safety of Cancer Signal Origin (CSO)-Guided Diagnostic\nWorkups Following Multi-Cancer Early Detection (MCED) Testing: Results from\nPATHFINDER 2 (PF2)\nAbstract Number: 1151\nPresentation Type: Rapid Oral\nDate/Time: Oct. 26, 2:45 p.m.-4:15 p.m.\nLocation: Salamanca Auditorium, Hall 10\n\nTitle: Diagnostic Workups Following a Positive Multi-Cancer Early Detection\n(MCED) Blood Test in Clinical Practice\nPresentation Number: 1164P\nPresentation Type: Poster\nDate/Time: Oct. 25, 12 p.m.-12:45 p.m.\n\nMore information about timing of the ESMO presentations can be found here\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4789959-1&h=1993774795&u=https%3A%2F%2Fcslide.ctimeetingtech.com%2Fesmo2026%2Fattendee%2Fconfcal%2Fsession%2Flist&a=here)\n.\n\nAbout GRAIL\nGRAIL is a healthcare company whose mission is to detect cancer early, when it\ncan be cured. GRAIL is focused on alleviating the global burden of cancer by\nusing the power of next-generation sequencing, population-scale clinical\nstudies, and state-of-the-art machine learning, software, and automation to\ndetect and identify multiple deadly cancer types in earlier stages. GRAIL's\ntargeted methylation-based platform can support the continuum of care for\nscreening and precision oncology, including multi-cancer early detection in\nsymptomatic patients, risk stratification, minimal residual disease detection,\nbiomarker subtyping, treatment and recurrence monitoring. GRAIL is\nheadquartered in Sunnyvale, Calif. with locations in Washington, D.C., North\nCarolina, and the United Kingdom.\n\nFor more information, visit grail.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4789959-1&h=1713412373&u=http%3A%2F%2Fwww.grail.com%2F&a=grail.com)\n.\n\nAbout Galleri(®)\nThe Galleri(®) multi-cancer early detection (MCED) test screens for more\nthan 50 cancer types, including many deadly cancers that currently lack\nscreening options, such as pancreatic, ovarian, and liver/bile duct\ncancers(1). The Galleri test is the only MCED test clinically proven through a\nrandomized controlled trial to increase earlier cancer detection (Stage I-III)\nand reduce Stage IV diagnoses - enabling more patients to have access to\npotentially curative treatment options(2). When added to standard-of-care\nscreening, the Galleri test reduced Stage IV diagnosis by more than 20% after\nthe first year of screening across all stageable cancers(2,)*. The Galleri\ntest increased cancer detection by screening four times versus standard of\ncare screening alone(2). The Galleri test has the lowest false positive rate\namong MCED tests** and the ability to predict the Cancer Signal Origin with\ngreater than 90% accuracy, helping guide efficient diagnostic\nevaluation(1-)(3). The Galleri test is backed by a robust clinical evidence\nprogram, with more than 380,000 participants across multiple studies,\nincluding the NHS-Galleri trial, the first and only randomized controlled\ntrial for an MCED test. The Galleri test has delivered consistent performance\nacross these studies. The Galleri test requires a prescription from a licensed\nhealthcare provider and should be used in addition to recommended cancer\nscreenings, such as mammography, colonoscopy, prostate-specific antigen (PSA)\ntest, cervical or lung cancer screening. The Galleri test is recommended for\nadults with an elevated risk for cancer, such as those aged 50 years or older.\n\nFor more information, visit galleri.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4789959-1&h=2832277109&u=http%3A%2F%2Fgalleri.com%2F&a=galleri.com)\n.\n\n*A statistically significant reduction was not observed in combined stage\nIII–IV diagnoses across three screening rounds for 12 cancer types\nresponsible for around two-thirds of cancer mortality in the US and UK.\n\n**Test performance metrics do not represent results of a head-to-head\ncomparative study. Separate studies have different designs, objectives, and\nparticipant populations, which limits the ability to draw conclusions about\ncomparative performance.\n\nImportant Galleri Safety Information\nThe Galleri test is recommended for use in adults with an elevated risk for\ncancer, such as those age 50 years or older. The test does not detect all\ncancers and should be used in addition to routine cancer screening tests\nrecommended by a healthcare provider. The Galleri test is intended to detect\ncancer signals and predict where in the body the cancer signal is located. Use\nof the test is not recommended in individuals who are pregnant, 21 years old\nor younger, or undergoing active cancer treatment. Results should be\ninterpreted by a healthcare provider in the context of medical history,\nclinical signs, and symptoms. A test result of No Cancer Signal Detected does\nnot rule out cancer. A test result of Cancer Signal Detected requires\nconfirmatory diagnostic evaluation by medically established procedures (e.g.,\nimaging) to confirm cancer. If cancer is not confirmed with further testing,\nit could mean that cancer is not present or testing was insufficient to detect\ncancer, including due to the cancer being located in a different part of the\nbody. False positive (a cancer signal detected when cancer is not present) and\nfalse negative (a cancer signal not detected when cancer is present) test\nresults do occur. Rx only.\n\nLaboratory/Test Information\nThe GRAIL clinical laboratory is certified under the Clinical Laboratory\nImprovement Amendments of 1988 (CLIA) and accredited by the College of\nAmerican Pathologists. The Galleri test was developed — and its performance\ncharacteristics were determined — by GRAIL. The Galleri test has not been\ncleared or approved by the Food and Drug Administration. The GRAIL clinical\nlaboratory is regulated under CLIA to perform high-complexity testing. The\nGalleri test is intended for clinical purposes.\n\nGRAIL Forward Looking Statements\nThis press release contains forward-looking statements. In some cases, you can\nidentify these statements by forward-looking words such as \"aim,\"\n\"anticipate,\" \"believe,\" \"continue,\" \"could,\" \"estimate,\" \"expect,\" \"intend,\"\n\"may,\" \"might,\" \"plan,\" \"potential,\" \"predict,\" \"should,\" \"would,\" or \"will,\"\nthe negative of these terms, and other comparable terminology. These\nforward-looking statements, which are subject to risks, uncertainties, and\nassumptions about us, may include statements related to the potential\nbenefits, uses and impacts of the Galleri test, comparability of clinical\nstudy results to a real world setting, benefits of population screening with\nexisting or future versions of Galleri, the substance, format and scope of the\nclinical data to be presented at the EDCC and ESMO Congress, and the\nevidentiary effect and clinical implications of additional clinical data and\nanalyses on the potential benefits, uses and impacts of the Galleri test,\namong others.\n\nThese statements are only predictions based on our current expectations and\nprojections about future events and trends. There are important factors that\ncould cause our actual results, level of activity, performance, or\nachievements to differ materially and adversely from those expressed or\nimplied by the forward-looking statements, including those factors and\nnumerous associated risks discussed under the sections entitled \"Risk Factors\"\nin our Annual Report on Form 10-K for the period ended December 31, 2025 and\nour subsequent Quarterly Reports on Form 10-Q. Moreover, we operate in a\ndynamic and rapidly changing environment. New risks emerge from time to time.\nIt is not possible for our management to predict all risks, nor can we assess\nthe impact of all factors on our business or the extent to which any factor,\nor combination of factors, may cause actual results, level of activity,\nperformance, or achievements to differ materially and adversely from those\ncontained in any forward-looking statements we may make.\n\nForward-looking statements relate to the future and, accordingly, are subject\nto inherent uncertainties, risks, and changes in circumstances that are\ndifficult to predict and many of which are outside of our control. Although we\nbelieve the expectations and projections expressed or implied by the\nforward-looking statements are reasonable, we cannot guarantee future results,\nlevel of activity, performance, or achievements. Our actual results, financial\ncondition and success in our business strategies and operations may differ\nmaterially from those indicated in the forward-looking statements. Except to\nthe extent required by law, we undertake no obligation to update any of these\nforward-looking statements after the date of this press release to conform our\nprior statements to actual results or revised expectations or to reflect new\ninformation or the occurrence of unanticipated events.\n\n(1) Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted\nmethylation-based multi-cancer early detection test using an independent\nvalidation set. Ann Oncol. 2021 Sep;32(9):1167-77. doi:\n10.1016/j.annonc.2021.05.806\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4789959-1&h=3964125602&u=https%3A%2F%2Fwww.annalsofoncology.org%2Farticle%2FS0923-7534(21)02046-9%2Ffulltext&a=10.1016%2Fj.annonc.2021.05.806)\n\n(2) Swanton C. NHS-Galleri: Primary Results From a Randomised Controlled\nTrial to Assess the Clinical Utility of a Multi-Cancer Early Detection (MCED)\nTest in Population Screening [presentation]. American Society of Clinical\nOncology (ASCO) Annual Meeting; 2026 May 29-June 2.\n\n(3) GRAIL, Inc. False positive rate. [Data on file: GR-2025-0256]\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/grail-to-present-new-data-from-nhs-galleri-and-pathfinder-2-at-edcc-and-esmo-congress-2026-302898855.html\n(https://www.prnewswire.com/news-releases/grail-to-present-new-data-from-nhs-galleri-and-pathfinder-2-at-edcc-and-esmo-congress-2026-302898855.html)\n\nSOURCE GRAIL, Inc.\n\n\n\nCorporate Communications, Kristen Ziese or Trish Rowland, pr@grail.com or Investor Relations, Alex Dobbin or Alexis Tosti, ir@grail.com\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1579281/Grail-Logo.jpg?id=OA2988272\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-10-05T20:01:00.100492227Z","server_sent_at_ms":1791230460100},"received_at":"2026-10-05T20:01:00.253Z","source_url":"https://www.prnewswire.com/news-releases/grail-to-present-new-data-from-nhs-galleri-and-pathfinder-2-at-edcc-and-esmo-congress-2026-302898855.html"},"analysis":{"id":"149526","press_release_id":"160962","analysis_json":{"industry":{"label":"Health Care Providers & Services","sector":"Health Care"},"redFlags":[],"eventType":"operations_update","narrative":"GRAIL will present eight abstracts spanning the NHS-Galleri trial and PATHFINDER 2 study at the Early Detection of Cancer Conference (Oct. 6-8, Edinburgh) and ESMO Congress 2026 (Oct. 23-27, Madrid).\n\nData include a rapid oral on safety and efficiency of Cancer Signal Origin-guided diagnostic workups, plus posters on detection of more than 200 cancers, performance across racial and ethnic groups, and reduced emergency-setting cancer diagnoses with annual Galleri screening.\n\nThe presentations extend the clinical evidence base for the Galleri MCED test ahead of commercial and reimbursement decisions, but contain no new efficacy data or regulatory milestones.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Conference data drops could move GRAL if NHS-Galleri preclinical-window findings support annual screening."},"keyFigures":{"drugName":"Galleri MCED test","customDimensions":{"cso_accuracy":"greater than 90%","abstracts_edcc":6,"abstracts_esmo":2,"cancers_screened":"more than 50 cancer types","stage_iv_reduction":"more than 20% after first year of screening","clinical_program_participants":"more than 380,000"}},"quotedText":"Ongoing analyses of PATHFINDER 2 and NHS-Galleri trial data continue to strengthen the evidence for integrating multi-cancer early detection into routine care","namedEntities":{"people":[{"name":"Josh Ofman","role":"CEO"}],"products":["Galleri","NHS-Galleri trial","PATHFINDER 2 study"],"companies":[{"name":"GRAIL, Inc.","ticker":"GRAL","relationship":"filer"},{"name":"European Society for Medical Oncology","relationship":"conference host"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Announcement of upcoming conference presentations of existing NHS-Galleri and PATHFINDER 2 data; supportive of Galleri's evidence base but no new results, regulatory, or financial events."},"tickerRelevance":{"others":[],"primary":"GRAL"},"globalImportance":25,"audienceRelevance":30,"eventTypeSecondary":["clinical_trial"],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"conference-data-announcement","sectorWeight":"biotech-diagnostics","issuerAuthored":true}},"event_type":"operations_update","event_type_secondary":["clinical_trial"],"sentiment":"bullish","material_impact_score":2,"narrative":"GRAIL will present eight abstracts spanning the NHS-Galleri trial and PATHFINDER 2 study at the Early Detection of Cancer Conference (Oct. 6-8, Edinburgh) and ESMO Congress 2026 (Oct. 23-27, Madrid).\n\nData include a rapid oral on safety and efficiency of Cancer Signal Origin-guided diagnostic workups, plus posters on detection of more than 200 cancers, performance across racial and ethnic groups, and reduced emergency-setting cancer diagnoses with annual Galleri screening.\n\nThe presentations extend the clinical evidence base for the Galleri MCED test ahead of commercial and reimbursement decisions, but contain no new efficacy data or regulatory milestones.","key_figures":{"drugName":"Galleri MCED test","customDimensions":{"cso_accuracy":"greater than 90%","abstracts_edcc":6,"abstracts_esmo":2,"cancers_screened":"more than 50 cancer types","stage_iv_reduction":"more than 20% after first year of screening","clinical_program_participants":"more than 380,000"}},"named_entities":{"people":[{"name":"Josh Ofman","role":"CEO"}],"products":["Galleri","NHS-Galleri trial","PATHFINDER 2 study"],"companies":[{"name":"GRAIL, Inc.","ticker":"GRAL","relationship":"filer"},{"name":"European Society for Medical Oncology","relationship":"conference host"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-05T20:01:05.468Z","global_importance":25,"audience_relevance":30,"importance_components":{"tickerTier":"small-cap","eventGravity":"conference-data-announcement","sectorWeight":"biotech-diagnostics","issuerAuthored":true}},"durationMs":5156,"modelName":"glm-5.3-flashx"}}